Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belnacasan

Drug Profile

Belnacasan

Alternative Names: UNII-00OLE78529; VX-765

Latest Information Update: 04 Feb 2014

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Aminobenzoic acids; Antipsoriatics; Dipeptides; Small molecules
  • Mechanism of Action Caspase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cardiovascular disorders; Epilepsy; Inflammation; Psoriasis

Most Recent Events

  • 31 Dec 2011 Vertex Pharmaceuticals initiates enrolment in a Phase-IIb trial for treatment-resistant epilepsy in USA (NCT01501383)
  • 02 Dec 2011 Adverse events and efficacy data from a phase II trial in Epilepsy presented at the 65th Annual Meeting of the American Epilepsy Society (AES-2011)
  • 10 Mar 2011 Efficacy and adverse events data from a phase II trial in Partial epilepsies released by Vertex Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top